What is it used for?
TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- talquetamabtalquetamab
- Form and strength
- INJECTION · 3 mg / 1.5 mL; INJECTION · 40 mg / 1 mLINJECTION · 3 mg / 1.5 mL; INJECTION · 40 mg / 1 mL
- Manufacturer / applicant
- JANSSEN BIOTECH, INC.JANSSEN BIOTECH, INC.
Injection 3 mg/1.5 mL (2 mg/mL) colorless to light yellow solution in a single-dose vial 40 mg/mL colorless to light yellow solution in a single-dose vialInjection 3 mg/1.5 mL (2 mg/mL) colorless to light yellow solution in a single-dose vial 40 mg/mL colorless to light yellow solution in a single-dose vial
Safety and clinical review
Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TALVEY. Initiate TALVEY treatment with step-up dosing to reduce the risk of CRS. Withhold TALVEY until CRS resolves or permanently discontinue based on severity . Neurologic toxicity, including …Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TALVEY. Initiate TALVEY treatment with step-up dosing to reduce the risk of CRS. Withhold TALVEY until CRS resolves or permanently discontinue based on severity . Neurologic toxicity, including …
- Cytokine Release Syndrome (CRS)Cytokine Release Syndrome (CRS)
- Neurologic Toxicity including ICANSNeurologic Toxicity including ICANS
- TECVAYLI and TALVEY REMSTECVAYLI and TALVEY REMS
- Oral Toxicity and Weight LossOral Toxicity and Weight Loss
- InfectionsInfections
- CytopeniasCytopenias
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is TALVEY used for?
TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of TALVEY should I ask about?
INJECTION · 3 mg / 1.5 mL; INJECTION · 40 mg / 1 mLINJECTION · 3 mg / 1.5 mL; INJECTION · 40 mg / 1 mL
Read the primary sourceWhat determines the price of TALVEY?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using TALVEY?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.